Razoxane 5ICRF-159) has been shown to have clear dose dependent efficacy in treatment of patients with psoriasis refractory to other conventional therapies. In an attempt to improve the therapeutic index of Razoxane, i.e. maintening high efficacy and lowering the dose-limiting neutropenia, its detrox-enantiomereICRF-187 has been developed. It is known that doses up till 1/3 of MTD (maximum treatment dose) do not cause any significant drop in peripheral leukocyte counts. This project has been designed to determine the following:
1. Confirmation of the efficacy and safety of i.v. administered, commercially available ICRF-187 (trademark CARDIOXANE in EU, ZINECARD in USA and CAN)
2. Development of a new drug formulation: cream or ointment for topical treatment of skin lesions.
3. Detailed study of pre-clinical and clinical efficacy of new formulation
4. Development of pharmacological, toxicological and clinical documentation necessary to support registration in EU countries.
Funding SchemeEAW - Exploratory awards
TN7 4DB Withyham